An electronic copy of the thesis may be ordered from the faculty up to 2 days prior to the public defence. Inquiries regarding the thesis after the public defence must be addressed to the candidate.
Trial Lecture – time and place
See Trial Lecture.
Adjudication committee
- First opponent: Associate Professor Katarina Steen Carlsson, Lund University, Sweden
- Second opponent: Associate Professor Søren Rud Kristensen, University of Southern Denmark
- Third member and chair of the evaluation committee: Professor II Giske Ursin, University of Oslo
Chair of the Defence
Tone Kristin Omsland, Professor, University of Oslo
Principal Supervisor
Hans Olav Melberg, Professor, UiT - The Arctic University of Norway
Summary
The overall aim of this thesis is to explore how real-world evidence can be used to support priority setting and planning in the cancer care. The thesis includes four published papers in which data from Norwegian health registries are used to study management of cancer, resource use and costs. In Paper 1, health care costs are estimated to NOK 21 billion, while lost productivity and the value of lost health amount to NOK 28 and 180 billion, respectively. The results from Paper II indicate that the treatment costs are highest during the initial treatment phase and in the terminal phase. Paper III examines the use of anti-cancer drugs end-of-life and provide evidence that fewer patients receive such treatment in Norway compared with other countries. The analyses in Paper IV shows that most of the gender differences in treatment costs end-of-life can be explained by differences in the type of cancer, age, and place of death. The four included papers demonstrate in various ways how real-world evidence can support health economic analyzes, which can provide information to support efficient and fair distribution of resources.
Additional information
Contact the research support staff.